Çelık R Gökçen Gözübatik, Köksal Ayhan, Şahın Buket, Şen Aysu, Sakalli Nazan Karagöz, Nalbantoğlu Mecbure
Department of Neurology, Bakırköy Research and Training Hospital for Neurologic and Psychiatric Diseases, İstanbul, Turkey.
Department of Neurology, Bilim University School of Medicine, İstanbul, Turkey.
Noro Psikiyatr Ars. 2020 Jan 6;57(1):33-36. doi: 10.29399/npa.24761. eCollection 2020 Mar.
In this study, we aimed to investigate the effect of uric acid on the disease, its severity and progression in ET patients with partially co-clinical features with Parkinson's disease (PD).
Serum UA levels of 87 consecutive ET patients were measured and were matched according to age and sex with 87 healthy controls. Fahn-Tolosa-Marin scale was used for the severity of tremor. Sociodemographic characteristics, type of ET, duration of disease, and treatment modalities were evaluated.
The mean uric acid level was calculated as 4.986±2.1458 mg/dL and 6.004±1.523 mg/dL in the patient and control groups, respectively (p≤0.005). The blood UA level of patients with sporadic (n: 61) ET was found to be lower than the familial ET (n: 26) (p≤0.005). The tremor severity of the family ET patients was lower than the sporadic ET. (n: 61) (p≤0.005). The mean blood UA level (4.429±1.216 mg/dL) in the patients with high total tremor severity scores (n: 48) was found lower than in the patients with low total tremor severity scores (n: 39) (5.673±2.106 mg/dL) (P=0.000). The serum UA level was significantly lower in the patients whose disease duration longer than 5 years than in patients whose duration of the disease was shorter than 5 years. 5.732±1.240 for ≥5 years; 6.438±0.286≤5 years) (P=0.001).
We hypothesize that as a result of high antioxidant properties of high serum uric acid levels, it is a biomarker that can show disease risk and progression in patients with ET as well as PD.
在本研究中，我们旨在调查尿酸对具有部分帕金森病（PD）共同临床特征的特发性震颤（ET）患者的疾病、严重程度及进展的影响。
测量了87例连续的ET患者的血清尿酸水平，并根据年龄和性别与87名健康对照进行匹配。使用Fahn-Tolosa-Marin量表评估震颤的严重程度。评估了社会人口统计学特征、ET类型、疾病持续时间和治疗方式。
患者组和对照组的平均尿酸水平分别计算为4.986±2.1458mg/dL和6.004±1.523mg/dL（p≤0.005）。发现散发性（n：61）ET患者的血尿酸水平低于家族性ET患者（n：26）（p≤0.005）。家族性ET患者的震颤严重程度低于散发性ET患者（n：61）（p≤0.005）。发现总震颤严重程度评分高的患者（n：48）的平均血尿酸水平（4.429±1.216mg/dL）低于总震颤严重程度评分低的患者（n：39）（5.673±2.106mg/dL）（P=0.000）。疾病持续时间超过5年的患者的血清尿酸水平显著低于疾病持续时间短于5年的患者。≥5年组为5.732±1.240；≤5年组为6.438±0.286）（P=0.001）。
我们推测，由于高血清尿酸水平具有高抗氧化特性，它是一种可显示ET以及PD患者疾病风险和进展的生物标志物。
